

Article

Can ECIS Biosensor Technology Be Used to Measure the Cellular Responses of Glioblastoma Stem cells?

Laverne Diana Robilliard ^{1,2,†}, Jane Yu ^{1,2,†}, Sung-Min Jun ^{1,2}, Akshata Anchan ^{1,2}, Graeme Finlay ^{1,3}, Catherine E. Angel ⁴ and Euan Scott Graham ^{1,2,*}

¹ Department of Molecular Medicine and Pathology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1025, North Island, New Zealand; l.robilliard@auckland.ac.nz (L.D.R.); jane.yu@auckland.ac.nz (J.Y.); sjun881@aucklanduni.ac.nz (S.-M.J.); a.anchan@auckland.ac.nz (A.A.); g.finlay@auckland.ac.nz (G.F.)

² Centre for Brain Research, University of Auckland, Auckland 1025, North Island, New Zealand

³ Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1025, North Island, New Zealand

⁴ School of Biological Sciences, Faculty of Science, University of Auckland, Auckland 1025, North Island, New Zealand; c.angel@auckland.ac.nz

* Correspondence: s.graham@auckland.ac.nz

† These authors contributed equally to this work.




Figure S1 Serum-derived and gCSC cell resistance on 96W1E+ ECIS arrays. Phase contrast images of NZB11, NZB12, NZB19, and NZB13 serum-derived and gCSC cells after 60 h of growth on 96W1E+ ECIS arrays. Images acquired at 20× magnification. Data are representative of three independent replicates.